Atreca, Inc. (NASDAQ:BCEL) Q4 2022 Earnings Call Transcript

Philippe Bishop: So yes, so obviously, we’re going to enroll and collect data until the study comes to fruition. I think we will report on the — when it’s appropriate by the end of the year of what our most up-to-date results would be. And I think the data cutoff of that typically requires a few weeks for us to be able to analyze the data and put it together.

John Orwin: Yes, I think maybe one of the challenges you might be alluding to, and I think that’s an important one is having sufficient follow-up to able to assess durability of response. So I think it might be a little bit easier in a way to make a no-go decision than it is a go decision. The no-go decision would be based on not seeing a level of activity for a given indication of program overall, that would lead you to not move forward in Phase 2. A go to Phase 2 decision is a clinical decision but it’s also a business decision. And I think that you could imagine a scenario where you’ve got responders or long-term stable disease and you want to give a little bit more time before making the decision to pull the trigger on an expensive Phase 2 program.

But I think our commitment is really to try to provide fairly regular update and get to a crisp decision by the end of this year, plus/minus when we basically don’t want to leave the study just open enroll in patients without making a decision to go to Phase 2 or possibly end program. I think we all feel pretty encouraged by the data that we’re seeing, the durability of the responses, the PFS that seems to favor patients who express target. But I also think it’s important for us to get to a decision because there’s an opportunity cost here when you look at the other molecules that we have that are going to in the next 18 months. Okay. Great. Well, thanks a lot. Much appreciate it, Kemp. Thanks, everyone, for your questions today and for joining the call.

And I look forward to additional updates in the future.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.